CSF2RA (GMR-alpha): A Promising Drug Target and Biomarker for Glioblastoma

CSF2RA (GMR-alpha): A Promising Drug Target and Biomarker for Glioblastoma

Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer, with a poor prognosis due to the high treatment resistance and the development of drug resistance. Despite advances in surgical and radiation treatments, the survival rate for GBM patients remains poor, with a five-year survival rate of only around 14%. Therefore, there is a need for new treatments that can improve the treatment outcomes for GBM patients.

One of the promising drug targets for GBM is the gene CSF2RA (GluF21), which encodes a protein known as GLI2R. GLI2R is a transmembrane protein that plays a critical role in the development and progression of GBM. It is expressed in various tissues and cell types, including brain, and has been involved in various cellular processes, including cell survival, angiogenesis, and inflammation.

Recent studies have shown that GLI2R is overexpressed in GBM tissues and that its overexpression is associated with poor prognosis. Therefore, targeting GLI2R has been identified as a potential therapeutic approach for GBM treatment.

CSF2RA (GMR-alpha) is a potential drug target for GBM, as it is a highly potent inhibitor of GLI2R. It has been shown to inhibit GLI2R-mediated signaling pathways, including the PI3K/Akt signaling pathway, which is involved in cell survival and angiogenesis.

In addition to its inhibitory effects on GLI2R, CSF2RA has been shown to have several other effects that make it a potential drug target for GBM. First, it has been shown to regulate the sprouting angiogenesis, which is a critical process in the development of new blood vessels that supply tumors. Second, it has been shown to promote the apoptosis of GBM cells, which may contribute to the tumor suppressor effect of CSF2RA.

Furthermore, CSF2RA has been shown to have anti-inflammatory effects, which may be beneficial for GBM patients with poor prognosis due to the high level of inflammation in GBM tissues.

In conclusion, CSF2RA (GMR-alpha) is a promising drug target for GBM, as it has been shown to inhibit GLI2R-mediated signaling pathways and has several other effects that make it a potential therapeutic approach for GBM treatment. Further studies are needed to confirm its efficacy and to determine its optimal dosing regimen.

Protein Name: Colony Stimulating Factor 2 Receptor Subunit Alpha

Functions: Low affinity receptor for granulocyte-macrophage colony-stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells

The "CSF2RA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CSF2RA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CSF2RB | CSF2RBP1 | CSF3 | CSF3R | CSGALNACT1 | CSGALNACT2 | CSH1 | CSH2 | CSHL1 | CSK | CSKMT | CSMD1 | CSMD2 | CSMD2-AS1 | CSMD3 | CSN1S1 | CSN1S2AP | CSN1S2BP | CSN2 | CSN3 | CSNK1A1 | CSNK1A1L | CSNK1A1P1 | CSNK1D | CSNK1E | CSNK1G1 | CSNK1G2 | CSNK1G2-AS1 | CSNK1G3 | CSNK2A1 | CSNK2A2 | CSNK2A3 | CSNK2B | CSPG4 | CSPG4P10 | CSPG4P11 | CSPG4P12 | CSPG4P13 | CSPG4P1Y | CSPG4P2Y | CSPG4P3Y | CSPG5 | CSPP1 | CSRNP1 | CSRNP2 | CSRNP3 | CSRP1 | CSRP2 | CSRP3 | CSRP3-AS1 | CST Complex | CST1 | CST11 | CST13P | CST2 | CST3 | CST4 | CST5 | CST6 | CST7 | CST8 | CST9 | CST9L | CST9LP1 | CSTA | CSTB | CSTF1 | CSTF2 | CSTF2T | CSTF3 | CSTL1 | CSTPP1 | CT45A1 | CT45A10 | CT45A2 | CT45A3 | CT45A5 | CT45A6 | CT45A9 | CT47A1 | CT47A10 | CT47A11 | CT47A12 | CT47A2 | CT47A3 | CT47A4 | CT47A5 | CT47A6 | CT47A7 | CT47A8 | CT47A9 | CT47B1 | CT55 | CT62 | CT66 | CT75 | CT83 | CTAG1A | CTAG1B | CTAG2